Neurocrine Biosciences Inc. (NBIX)
-NasdaqGS 11.75 
0.24(2.00%) May 17, 4:00PM EDT|After Hours
:
11.75 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 11.99 |
|---|
| Open: | 12.03 |
|---|
| Bid: | 9.36 x 100 |
|---|
| Ask: | 12.60 x 100 |
|---|
| 1y Target Est: | 15.00 |
|---|
| Beta: | 0.36 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 11.68 - 12.10 |
|---|
| 52wk Range: | 6.25 - 12.85 |
|---|
| Volume: | 862,897 |
|---|
| Avg Vol (3m): | 520,627 |
|---|
| Market Cap: | 784.10M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.09 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Neurocrine Biosciences' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nearsat Seeking Alpha(Fri, May 10)
- NEUROCRINE BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 10)
- Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Thu, May 9)
- Neurocrine Biosciences Inc. Stock Downgraded (NBIX)at TheStreet(Tue, May 7)
- 1 Winner and 4 Losers from This Week’s Earnings Stormat Wall St. Cheat Sheet(Sat, May 4)
- Neurocrine Biosciences CEO Discuses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 3)
- Neurocrine Biosciences Earnings: Here’s Why Investors are Selling Shares Nowat Wall St. Cheat Sheet(Thu, May 2)
- Neurocrine Biosciences Reports First Quarter 2013 ResultsPR Newswire(Thu, May 2)
- NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 2)
- Q1 2013 Neurocrine Biosciences Earnings Release - After Market CloseCCBN(Thu, May 2)
- Wall Street Transcript Interview with Ian Somaiya, Managing Director and Senior Research Analyst at Piper Jaffray & Co.: Identifying Hidden Value and Market Opportunities in Biotech CompaniesWall Street Transcript(Tue, Apr 30)
- Neurocrine Biosciences Announces Conference Call And Webcast To Present First Quarter 2013 Financial ResultsPR Newswire(Fri, Apr 26)
- Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare ConferencePR Newswire(Wed, Apr 24)
- 2 Pharmaceutical Buys Under $15 With Strong Catalystsat Seeking Alpha(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 18.78 |
|---|
| Ex-Dividend Date: | 29-Dec-95 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.79 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -0.22 |
|---|
Business Summary
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
View More